News
Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.
Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political support erode.
With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...
Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...
This story first appeared in the UNAIDS Global AIDS Update 2025 report.
Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...
Opinion
2dOpinion
The Star on MSNNYIKAL, LANG'AT & OTINDO: Kenya at crossroads - Call for courage in HIV response
Conference on HIV Science on July 17 in Kigali, one message echoed with urgency across Africa—and especially in Kenya: the global HIV response is at a turning point. IAS 2025 was not just a conference ...
I could only feel shocked at first, like the air was knocked out of my body. My first thought was: My life is over. This is ...
The Republican-led Senate rescued funding for PEPFAR in a package of spending cuts last month, but the HIV-prevention program ...
LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...
Scott Blades is a longtime champion of care for people in the Tucson community who are impacted by HIV and AIDS.
Countries worldwide must step up to support the fight against HIV or face the “ticking time bomb” left by the wholesale withdrawal of US funding, warns UNAIDS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results